Development of a PET Prostate-Specific Membrane Antigen Imaging Agent: Preclinical Translation for Future Clinical Application
Abstract
The overall objective of this research project is to collect chemistry and preclinical data on two promising new small-molecule peptidomimetic imaging agents labeled with positron emitting fluorine-18. These data will enable the filing of an exploratory IND (expIND; phase 0) application to the FDA by the end of the funding period. The small molecule imaging agents under study home to prostate specific membrane antigen (PSMA) that is prevalent on a majority of prostate cancers. The availability of these imaging agents will support diagnosis and staging of prostate cancer without the need for a biopsy as well as provide valuable information to guide therapeutic intervention and monitor the treatment outcome.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2017
- Accession Number
- AD1048460
Entities
People
- Henry F VanBrocklin
Organizations
- University of California, San Francisco